On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the ?Company?) announced the appointment of Mardi C. Dier as Senior Vice President of the Company, effective March 11, 2024. In such capacity, Ms. Dier will serve as the ?principal financial officer? and ?principal accounting officer?

of the Company for purposes of filings with the Securities and Exchange Commission. Ms. Dier joined the Company as an employee in a Senior Advisor role on February 27, 2024. Ms. Dier, age 60, was most recently Chief Financial Officer of Acelyrin, Inc., where she completed the company?s $621 million initial public offering before departing in August 2023.

Prior to that, Ms. Dier was Chief Financial Officer and Executive Vice President of Ultragenyx, responsible for leading the corporate strategy, FP&A, accounting, tax, investor relations, global corporate communications and information technology functions. Ultragenyx?s employee base grew 50% during her tenure, expanding its global commercial presence in the U.S., Latin America, Canada, Europe and Japan. She joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion), where she served as Chief Financial Officer for 14 years and, most recently, as Chief Business Officer and Chief Financial Officer.

Over the course of her time at Portola, Ms. Dier oversaw a wide range of functions and helped scale the organization from one site with fewer than 100 employees to a global organization with multiple sites in the U.S. and Europe and over 450 employees. Prior to Portola, she served as Vice President of Investor Relations at Chiron Corporation until its acquisition by Novartis. Earlier in her career, she worked as an investment banker at Prudential Securities and, prior to that, was in the audit department of KPMG Peat Marwick.

Ms. Dier serves on the Boards of Directors of ORIC Pharmaceuticals, Prelude Therapeutics, Synthekine, Inc. and Health Care Royalty and is a member of the Board of Advisors for the Anderson School of Management at the University of California, Los Angeles (UCLA). She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at UCLA. In addition, Brian J. Lynch, Senior Vice President and General Counsel, will be departing the Company after a transitional period expected to conclude on May 31, 2024.

If prior to such date the Company appoints a successor to Mr. Lynch, it is anticipated that Mr. Lynch would remain employed by the Company in a Senior Advisor role for the remainder of the transition period to ensure a smooth transition of responsibilities to his successor.